{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=dose+level+1&page=32", "query": { "intervention": "dose level 1", "page": 32 }, "page_size": 10 }, "pagination": { "page": 32, "page_size": 10, "total_count": 29101, "total_pages": 2911, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=dose+level+1&page=33&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=dose+level+1&page=31&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-15T09:00:10.672Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06832878", "title": "Postoperative Oral Tranexamic Acid in Patients Undergoing Primary Total Joint Arthroplasty", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Arthroplasty" ], "interventions": [ { "name": "Oral Tranexamic Acid", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 101, "start_date": "2026-06-01", "completion_date": "2027-06", "has_results": false, "last_update_posted_date": "2026-08-10", "last_synced_at": "2026-11-15T09:00:10.672Z", "location_count": 1, "location_summary": "Scottsdale, Arizona", "locations": [ { "city": "Scottsdale", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT06832878" }, { "nct_id": "NCT00570778", "title": "Efficacy and Safety of QVA149 in Patients With Chronic Obstructive Pulmonary Disease (COPD)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic Obstructive Pulmonary Disease (COPD)" ], "interventions": [ { "name": "indacaterol/glycopyrrolate", "type": "DRUG" }, { "name": "indacaterol", "type": "DRUG" }, { "name": "placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": null, "sex": "ALL", "summary": "40 Years and older" }, "enrollment_count": 154, "start_date": "2007-12", "completion_date": "2008-09", "has_results": true, "last_update_posted_date": "2018-07-26", "last_synced_at": "2026-11-15T09:00:10.672Z", "location_count": 3, "location_summary": "St Louis, Missouri • Charlotte, North Carolina • Raleigh, North Carolina", "locations": [ { "city": "St Louis", "state": "Missouri" }, { "city": "Charlotte", "state": "North Carolina" }, { "city": "Raleigh", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00570778" }, { "nct_id": "NCT04816643", "title": "Study to Evaluate the Safety, Tolerability, and Immunogenicity of an RNA Vaccine Candidate Against COVID-19 in Healthy Children", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "SARS-CoV-2 Infection, COVID-19" ], "interventions": [ { "name": "Biological/Vaccine: BNT162b2 10mcg", "type": "BIOLOGICAL" }, { "name": "BNT162b2 20mcg", "type": "BIOLOGICAL" }, { "name": "BNT162b2 30mcg", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "OTHER" }, { "name": "Biological/Vaccine: BNT162b2 3mcg", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "BioNTech SE", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "6 Months", "maximum_age": "15 Years", "sex": "ALL", "summary": "6 Months to 15 Years" }, "enrollment_count": 11837, "start_date": "2021-03-24", "completion_date": "2023-12-08", "has_results": true, "last_update_posted_date": "2026-05-28", "last_synced_at": "2026-11-15T09:00:10.672Z", "location_count": 90, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 67 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Madera", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04816643" }, { "nct_id": "NCT05911308", "title": "Abequolixron (RGX-104) and Durvalumab in Lung Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non-Small Cell Lung Cancer" ], "interventions": [ { "name": "Durvalumab", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Abequolixron", "type": "DRUG" }, { "name": "Abraxane", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "UNC Lineberger Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1, "start_date": "2024-04-01", "completion_date": "2025-02-27", "has_results": false, "last_update_posted_date": "2025-03-21", "last_synced_at": "2026-11-15T09:00:10.672Z", "location_count": 1, "location_summary": "Chapel Hill, North Carolina", "locations": [ { "city": "Chapel Hill", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT05911308" }, { "nct_id": "NCT02682225", "title": "Crossover Study to Evaluate the Abuse Potential of Intranasal Esketamine Compared to Racemic Intravenous Ketamine in Nondependent, Recreational Drug Users", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Drug Abuse" ], "interventions": [ { "name": "Intravenous placebo", "type": "DRUG" }, { "name": "Intranasal placebo", "type": "DRUG" }, { "name": "Intravenous racemic ketamine", "type": "DRUG" }, { "name": "Esketamine 112 mg", "type": "DRUG" }, { "name": "Esketamine 84 mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 55, "start_date": "2016-03-25", "completion_date": "2017-01-09", "has_results": false, "last_update_posted_date": "2025-04-27", "last_synced_at": "2026-11-15T09:00:10.672Z", "location_count": 1, "location_summary": "Salt Lake City, Utah", "locations": [ { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT02682225" }, { "nct_id": "NCT03407976", "title": "Apatinib With Pembrolizumab in Previously Treated Advanced Malignancies", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Malignancies", "Urothelial Carcinoma", "MSI-H or dMMR Solid Tumors", "Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma" ], "interventions": [ { "name": "Apatinib", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Utah", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 5, "start_date": "2018-06-19", "completion_date": "2020-07-02", "has_results": false, "last_update_posted_date": "2020-07-15", "last_synced_at": "2026-11-15T09:00:10.672Z", "location_count": 1, "location_summary": "Salt Lake City, Utah", "locations": [ { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT03407976" }, { "nct_id": "NCT06097676", "title": "An Abuse Potential Study of Orally Administered HORIZANT in Healthy, Non-dependent, Recreational Drug Users", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Abuse Potential" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "Alprazolam 2 mg", "type": "DRUG" }, { "name": "Gabapentin Enacarbil Immediate Release (GE-IR) 200 mg", "type": "DRUG" }, { "name": "Gabapentin Enacarbil Immediate Release (GE-IR) 450 mg", "type": "DRUG" }, { "name": "Gabapentin Enacarbil Immediate Release (GE-IR) 700 mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Arbor Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 86, "start_date": "2021-09-28", "completion_date": "2022-06-30", "has_results": true, "last_update_posted_date": "2024-08-12", "last_synced_at": "2026-11-15T09:00:10.672Z", "location_count": 1, "location_summary": "Overland Park, Kansas", "locations": [ { "city": "Overland Park", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06097676" }, { "nct_id": "NCT03446040", "title": "An Investigational Immunotherapy Study of BMS-986258 Alone and in Combination With Nivolumab in Participants With Solid Cancers That Are Advanced or Have Spread", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Cancer" ], "interventions": [ { "name": "BMS-986258", "type": "BIOLOGICAL" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "rHuPH20", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 92, "start_date": "2018-03-08", "completion_date": "2024-08-29", "has_results": true, "last_update_posted_date": "2025-09-18", "last_synced_at": "2026-11-15T09:00:10.672Z", "location_count": 10, "location_summary": "Los Angeles, California • Aurora, Colorado • Iowa City, Iowa + 6 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Iowa City", "state": "Iowa" }, { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT03446040" }, { "nct_id": "NCT00131989", "title": "Sorafenib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Chronic Myelogenous Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Adult Acute Basophilic Leukemia", "Adult Acute Eosinophilic Leukemia", "Adult Acute Megakaryoblastic Leukemia (M7)", "Adult Acute Minimally Differentiated Myeloid Leukemia (M0)", "Adult Acute Monocytic Leukemia (M5b)", "Adult Acute Myeloblastic Leukemia With Maturation (M2)", "Adult Acute Myeloblastic Leukemia Without Maturation (M1)", "Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities", "Adult Acute Myeloid Leukemia With Del(5q)", "Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)", "Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)", "Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)", "Adult Acute Myelomonocytic Leukemia (M4)", "Adult Erythroleukemia (M6a)", "Adult Pure Erythroid Leukemia (M6b)", "Recurrent Adult Acute Lymphoblastic Leukemia", "Recurrent Adult Acute Myeloid Leukemia" ], "interventions": [ { "name": "sorafenib tosylate", "type": "DRUG" }, { "name": "pharmacological study", "type": "OTHER" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 48, "start_date": "2005-06", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-01-09", "last_synced_at": "2026-11-15T09:00:10.672Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00131989" }, { "nct_id": "NCT07487168", "title": "Safety and Efficacy of PIPAC Using Single Agent Mitomycin in Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Peritoneal Carcinomatosis" ], "interventions": [ { "name": "Mitomycin C (MMC)", "type": "DRUG" }, { "name": "Pressurized Intraperitoneal Aerosolized Chemotherapy (PIPAC)", "type": "DEVICE" } ], "intervention_types": [ "DRUG", "DEVICE" ], "sponsor": "H. Lee Moffitt Cancer Center and Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 24, "start_date": "2026-08-05", "completion_date": "2028-03", "has_results": false, "last_update_posted_date": "2026-09-16", "last_synced_at": "2026-11-15T09:00:10.672Z", "location_count": 1, "location_summary": "Tampa, Florida", "locations": [ { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT07487168" } ] }